



## Post Authorisation Assessments

### Clavaseptin 750 mg Palatable Tablets for Dogs Vm 06462/3004

26 March 2026	Submission of an updated CEP for the manufacture of an active substance.
25 July 2025	Change in legal entity of MA holder from Vetoquinol UK Limited, Steadings Barn, Pury Hill Business Park, Nr. Alderton, Towcester, Northamptonshire, NN12 7LS to Vetoquinol SA, 34 Rue de Chene Sainte-Anne, Magny-Vernois, 70200 Lure, France.
25 June 2025	Additional indications in dogs and cats. One-off alignment of the product information with version 9.0* of the QRD templates i.e. major update of the QRD template.
06 June 2025	Minor changes to an approved test procedure for the finished product.
09 May 2025	Change in the specification parameters or limits of an excipient -addition of a new specification parameter to the specification with its corresponding test method. Change in the specification parameters or limits of an excipient-tightening of specification limits. Deletion of a non-significant specification parameter in the specification parameters or limits of an excipient. Minor changes to an approved test procedure for an excipient.
26 February 2025	Introduction of a retest period of the active substance where none is specified in the Ph. Eur. Certificate of Suitability.
14 December 2024	Submission of updated CEP for an active substance manufacturer.
14 December 2023	Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV). Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in this Annex. (NI)
25 July 2023	Changes to the labelling of the finished product.
30 June 2023	Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product: - Change in the holding time of an intermediate or bulk product (if applicable).
24 March 2023	Minor changes to an approved test procedure the finished product.